| Schedule of calculation of basic and diluted net loss per share |
The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented (in thousands, except per share data): | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2025 | | 2024 | | 2025 | | 2024 | | | | | | | | | | | Numerator: | | | | | | | | | | Net loss | | $ | (290,509) | | | $ | (323,021) | | | $ | (605,150) | | | $ | (452,269) | | | Dividends and accretion on Series C redeemable convertible preferred stock | | — | | | (15,596) | | | (28,722) | | | (15,596) | | | Net loss attributable to common stockholders, basic | | $ | (290,509) | | | $ | (338,617) | | | $ | (633,872) | | | $ | (467,865) | | | Change in fair value of common stock warrants | | — | | | — | | | (26,845) | | | | | Net loss attributable to common stockholders, diluted | | $ | (290,509) | | | $ | (338,617) | | | $ | (660,717) | | | $ | (467,865) | | | Denominator: | | | | | | | | | | Weighted-average shares used in computing net loss attributable to common stockholders, basic | | 486,591 | | 209,626 | | 366,765 | | 209,560 | | Effect of dilutive securities: | | | | | | | | | | Common stock warrants | | — | | | — | | | 1,842 | | | — | | | Weighted-average shares used in computing net loss attributable to common stockholders, diluted | | 486,591 | | 209,626 | | 368,607 | | 209,560 | | Net loss per share attributable to common stockholders, basic | | $ | (0.60) | | | $ | (1.62) | | | $ | (1.73) | | | $ | (2.23) | | | Net loss per share attributable to common stockholders, diluted | | $ | (0.60) | | | $ | (1.62) | | | $ | (1.79) | | | $ | (2.23) | |
|
| Schedule of antidilutive securities excluded from computation |
The number of securities that were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive are as follows (in thousands): | | | | | | | | | | | | | | | | | As of June 30, | | | 2025 | | 2024 | | | | | | | Redeemable convertible preferred stock | | — | | 188,684 | | Outstanding convertible notes | | — | | 24,544 | | Outstanding stock options | | 44,480 | | 49,949 | | Outstanding RSUs and RSAs | | 27,146 | | — | | | Outstanding warrants to purchase common stock | | 4,337 | | 4,337 | | ESPP | | 147 | | — | | | Total | | 76,110 | | 267,514 |
|